BIAF
Companies
NASDAQ
BioAffinity Technologies Inc.
Health Care
$0.25
-$0.66 (-72.41%)
Price Chart
Overview
About BIAF
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Market Cap
$26.1M
Volume
14.5M
Avg. Volume
4.9M
P/E Ratio
-1.1666666
Dividend Yield
0.00%
Employees
38.0
Company Information
Latest News for BIAF
Risk & Correlation Analysis
Market Correlation
0.38
Low Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BIAF shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025